Lilia Cojuhari

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

Michel Bazinet, Victor Pântea, Valentin Cebotarescu et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 249 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +11

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy

Michel Bazinet, Victor Pântea, Gheorghe Plăcintă et al. · Gastroenterology · 2020 · 232 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection

Michel Bazinet, Victor Pântea, Valentin Cebotarescu et al. · Hepatology Communications · 2020 · 84 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg

Louis Shekhtman, Scott J. Cotler, Leeor Hershkovich et al. · Scientific Reports · 2020 · 35 citations · Full text

Pharmacy, Infectious Diseases, Pharmacokinetics +16

Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study

Michel Bazinet, Victor Pântea, Valentin Cebotarescu et al. · Journal of Hepatology · 2018 · 25 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17